Panbela Therapeutics Inc (PBLA)

[Backstabbed]

$PBLA NEWS!! Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)

https://www.otcmarkets.com/stock/PBLA/news/story?e&id=2461922

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Association for Cancer Research (AACR), which will be held April 14-19, 2023. The work reflects the Company’s on-going collaboration with Johns Hopkins University School of Medicine.
Details of the presentation are as follows:

Poster Presentation

Title: Evaluating the efficacy of spermine analogue ivospemin (SBP-101) in combination with chemotherapy in ovarian cancer

Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases
Session Date and Time: Tuesday Apr 18, 2023, 1:30 PM - 5:00 PM
Location: Section 15
Poster Board Number: 22
Abstract #: 4944
Additional meeting information can be found on the AACR website: Abstracts | AACR Annual Meeting 2023 | April 14-19, 2023 | Orlando, Florida

The abstract and poster will also be available on the Company's website at https://panbela.com/events-presentations/ once the information has been released by AACR